as 11-14-2024 9:38am EST
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
More About Our RLMD ML Model...
What kind of parameters do you use to train RLMD stocks ML model?
To train our stocks RLMD ML model, we use historical data with over 25 parameters, including volume indicators, volatility indicators, momentum indicators, trend indicators, and other metrics.
How often do you update RLMD ML model?
We update our ML model either weekly or biweekly, depending on the market capitalization of the stocks, using TensorFlow, typically over the weekend.
Why is the accuracy of your RLMD model low?
Unfortunately, our current data provider offers limited historical data, which impacts the accuracy of our ML model. However, as we continue to gather more data over time and add more indicators, we expect the accuracy of our model to improve.
How can I provide and share more data with you to increase your ML model accuracy?
We would greatly appreciate your contribution. Please send an email to [email protected]
Do you offer an ML model for shorter time periods, such as 5 minutes or 15 minutes?
Yes, we offer it for strategy purposes only, with intervals: 1 minute, 2 minutes, 5 minutes, 15 minutes, and 30 minutes etc.
Can I rely on your ML model to make financial decisions regarding buying or selling stocks, or is it only intended for learning purposes?
Our ML model is primarily designed for educational purposes and is not intended to provide financial advice. We strongly recommend consulting with a financial advisor before making any buying or selling decisions.
Share on Social Networks:
Disclaimer
Our RLMD ML model is developed exclusively for educational purposes. Any information presented on this page regarding the '"RLMD Forecast & Prediction for November 14, 2024 Relmada Therapeutics Inc." should not be considered as financial advice or as a recommendation to buy or sell stocks. It is provided strictly for educational purposes. Investing in stocks involves significant risks, and decisions should be made only after careful consideration and consultation with a qualified financial advisor.